vs
Side-by-side financial comparison of ISABELLA BANK CORP (ISBA) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.
Strata Critical Medical, Inc. is the larger business by last-quarter revenue ($22.7M vs $21.2M, roughly 1.1× ISABELLA BANK CORP). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs 14.3%). ISABELLA BANK CORP produced more free cash flow last quarter ($23.3M vs $-10.2M). Over the past eight quarters, ISABELLA BANK CORP's revenue compounded faster (12.6% CAGR vs -33.6%).
The Bank of the Philippine Islands is a universal bank in the Philippines. It is the oldest bank in both the Philippines and Southeast Asia. It is the fourth largest bank in terms of assets, the second largest bank in terms of market capitalization, and one of the most profitable banks in the Philippines.
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
ISBA vs SRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $22.7M |
| Net Profit | $4.7M | — |
| Gross Margin | — | -0.9% |
| Operating Margin | 32.2% | -18.4% |
| Net Margin | 22.2% | — |
| Revenue YoY | 14.3% | 361.2% |
| Net Profit YoY | 17.4% | — |
| EPS (diluted) | $0.64 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.2M | $22.7M | ||
| Q3 25 | $20.5M | $49.3M | ||
| Q2 25 | $18.8M | $70.8M | ||
| Q1 25 | $18.1M | $54.3M | ||
| Q4 24 | $18.5M | $-8.7M | ||
| Q3 24 | $18.0M | $36.1M | ||
| Q2 24 | $17.2M | $67.9M | ||
| Q1 24 | $16.7M | $51.5M |
| Q4 25 | $4.7M | — | ||
| Q3 25 | $5.2M | $57.4M | ||
| Q2 25 | $5.0M | $-3.7M | ||
| Q1 25 | $3.9M | $-3.5M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $3.3M | $-2.0M | ||
| Q2 24 | $3.5M | $-11.3M | ||
| Q1 24 | $3.1M | $-4.2M |
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
| Q4 25 | 32.2% | -18.4% | ||
| Q3 25 | 30.7% | -11.4% | ||
| Q2 25 | 32.8% | -7.0% | ||
| Q1 25 | 26.9% | -14.0% | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 21.3% | -19.7% | ||
| Q2 24 | 23.9% | -17.9% | ||
| Q1 24 | 21.8% | -19.2% |
| Q4 25 | 22.2% | — | ||
| Q3 25 | 25.6% | 116.5% | ||
| Q2 25 | 26.7% | -5.3% | ||
| Q1 25 | 21.9% | -6.4% | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 18.2% | -5.4% | ||
| Q2 24 | 20.3% | -16.7% | ||
| Q1 24 | 18.7% | -8.2% |
| Q4 25 | $0.64 | $-0.11 | ||
| Q3 25 | $0.71 | $0.70 | ||
| Q2 25 | $0.68 | $-0.05 | ||
| Q1 25 | $0.53 | $-0.04 | ||
| Q4 24 | $0.54 | $-0.11 | ||
| Q3 24 | $0.44 | $-0.03 | ||
| Q2 24 | $0.46 | $-0.15 | ||
| Q1 24 | $0.42 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $26.0M | $31.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.4M | $279.1M |
| Total Assets | $2.2B | $325.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.0M | $31.0M | ||
| Q3 25 | $161.3M | $22.8M | ||
| Q2 25 | $108.6M | $58.8M | ||
| Q1 25 | $69.2M | $34.8M | ||
| Q4 24 | $24.5M | $18.4M | ||
| Q3 24 | $27.4M | $20.0M | ||
| Q2 24 | $23.6M | $26.3M | ||
| Q1 24 | $25.2M | $36.8M |
| Q4 25 | $231.4M | $279.1M | ||
| Q3 25 | $227.4M | $283.0M | ||
| Q2 25 | $220.5M | $223.1M | ||
| Q1 25 | $215.6M | $219.7M | ||
| Q4 24 | $210.3M | $221.9M | ||
| Q3 24 | $213.0M | $233.5M | ||
| Q2 24 | $202.2M | $229.4M | ||
| Q1 24 | $200.7M | $236.6M |
| Q4 25 | $2.2B | $325.5M | ||
| Q3 25 | $2.3B | $335.1M | ||
| Q2 25 | $2.2B | $257.9M | ||
| Q1 25 | $2.1B | $250.6M | ||
| Q4 24 | $2.1B | $256.7M | ||
| Q3 24 | $2.1B | $282.9M | ||
| Q2 24 | $2.1B | $280.3M | ||
| Q1 24 | $2.1B | $282.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.8M | $-8.3M |
| Free Cash FlowOCF − Capex | $23.3M | $-10.2M |
| FCF MarginFCF / Revenue | 110.2% | -44.7% |
| Capex IntensityCapex / Revenue | 16.4% | 8.1% |
| Cash ConversionOCF / Net Profit | 5.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $36.0M | $-58.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.8M | $-8.3M | ||
| Q3 25 | $2.7M | $-37.3M | ||
| Q2 25 | $7.8M | $-3.1M | ||
| Q1 25 | $4.7M | $-246.0K | ||
| Q4 24 | $19.6M | $-1.8M | ||
| Q3 24 | $3.6M | $6.4M | ||
| Q2 24 | $5.5M | $8.4M | ||
| Q1 24 | $3.4M | $-15.6M |
| Q4 25 | $23.3M | $-10.2M | ||
| Q3 25 | $1.7M | $-40.1M | ||
| Q2 25 | $7.2M | $-5.4M | ||
| Q1 25 | $3.7M | $-2.9M | ||
| Q4 24 | $17.5M | $-6.3M | ||
| Q3 24 | $3.2M | $-3.0M | ||
| Q2 24 | $5.1M | $-7.7M | ||
| Q1 24 | $2.6M | $-16.4M |
| Q4 25 | 110.2% | -44.7% | ||
| Q3 25 | 8.5% | -81.4% | ||
| Q2 25 | 38.5% | -7.6% | ||
| Q1 25 | 20.6% | -5.3% | ||
| Q4 24 | 94.6% | 72.7% | ||
| Q3 24 | 17.7% | -8.2% | ||
| Q2 24 | 29.8% | -11.4% | ||
| Q1 24 | 15.7% | -31.8% |
| Q4 25 | 16.4% | 8.1% | ||
| Q3 25 | 5.0% | 5.7% | ||
| Q2 25 | 3.2% | 3.2% | ||
| Q1 25 | 5.5% | 4.8% | ||
| Q4 24 | 11.4% | -52.6% | ||
| Q3 24 | 2.0% | 25.8% | ||
| Q2 24 | 2.4% | 23.8% | ||
| Q1 24 | 4.9% | 1.6% |
| Q4 25 | 5.72× | — | ||
| Q3 25 | 0.52× | -0.65× | ||
| Q2 25 | 1.56× | — | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 4.91× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.59× | — | ||
| Q1 24 | 1.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ISBA
Segment breakdown not available.
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
